High-Dose Vitamin C Treatment in Critically Ill COVID-19 Patients
Condition: Respiratory Distress Syndrome, Adult; Covid19
MeSH terms: COVID-19; Respiratory Distress Syndrome; Respiratory Distress Syndrome, Newborn; Acute Lung Injury
Study type: Observational

Summary: 
      Acute respiratory failure due to COVİD-19 pneumonia has poor prognosis and high mortality .
      Both the lack of an effective antiviral treatment and the low level evidence of the
      recommendations presented in the guidelines on other treatment methods have highlighted
      supportive treatments. Studies suggest that high-dose vitamin C treatment reduces mortality
      in patients with sepsis and ARDS, and may also be beneficial in COVİD-19 disease. In the
      study; the investigator aimed to determine the effect of Vitamin C on short-term mortality
      and length of intensive care stay in COVID-19 patients.
    

Detailed description: 
      SARS-CoV-2 causes tissue damage in the endothelium and epithelium, increased vascular
      permeability and increased plasma levels of IL-6, IL-2, IL-7, IL-10 causing interstitial
      fibrosis in the lung is considered. Considering these factors in pathogenesis, a picture with
      high mortality from acute respiratory failure to severe ARDS emerges in critically ill
      COVID-19 patients. However, despite numerous studies, an effective antiviral treatment has
      not yet been found in COVID-19 disease. The low level of evidence for the recommendations
      presented in the guidelines on both treatment and mechanical ventilation has brought
      supportive treatments to the agenda. Recently, many articles have been published on the
      potential effects of anti-inflammatory and antioxidant treatments such as high-dose vitamin
      C, vitamin D, zinc and ozone therapy. In particular, high-dose intravenous vitamin C
      treatment is inexpensive, easily accessible, and it reduces mortality in patients with sepsis
      and ARDS in studies, suggesting that it may be beneficial in COVID-19 disease. this is a
      retrospective cohort study. The main goal of the study; to compare patients who did not
      receive high-dose vitamin C treatment in the first period of the epidemic and those who
      received treatment in the next period. the investigator aimed to determine the effect of
      Vitamin C on short-term mortality and length of stay in intensive care in critically ill
      COVID-19 patients. All patients' data on age, gender, body mass index, comorbidities
      (diabetes mellitus, hypertension, coronary artery disease, chronic obstructive pulmonary
      disease, other), PaO2 / FiO2 ratios, SOFA scores, ferritin, C-Reactive Protein,
      procalcitonin, lactate, neutrophil and lymphocyte values will be collected by scanning the
      hospital information system.
    

Intervention name(s): Ascorbic acid
Intervention type(s): Drug
Intervention description(s): The daily administration of 6 grams of vitamin C intravenously in 4 equal doses every 6 hours occurred and the treatment lasted 96 hours. Vials containing 1.5 gr vitamin C were placed in 100 cc 5% dextrose and infused intravenously in 30-60 minutes. Prepared serum bottles and sets are wrapped with aluminum foil in order to protect them from sunlight.
Intervention MeSH terms: Ascorbic Acid
Observational model: Cohort
Time perspective: Retrospective
Sampling method: Non-Probability Sample
Study population: 
        patients who admitted to the intensive care unit with the diagnosis of acute respiratory
        failure due to COVID-19 pneumonia
      
Keywords: coronavirus disease 2019; Ascorbic Acid; intensive care